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ABSTRACT
Objective. The present study aimed 
at evaluating the efficacy of abatacept 
(ABA) compared to tocilizumab (TCZ), 
assumed as a gold standard biologic 
treatment in the management of pa-
tients with giant cell arteritis (GCA).
Methods. Thirty-three biospy-proven 
GCA consecutive patients were pro-
spectively collected. Odd patients (from 
1 to 33) were assigned to TCZ, given ei-
ther intravenously (IV 8 mg/kg/month), 
#8 cases, or subcutaneously (SC 162 
mg/week) #9, based on patient’s prefer-
ence. ABA was administered subcuta-
neously at the dose of 125 mg/week in 
16 even patients (from 2 to 32). Biologi-
cal therapies were prescribed in addi-
tion to oral prednisone. 
Results. A single biologic agent was 
administered in 28 patients out of 33 
(85%) (8 TCZ IV, 9 TCZ SC and 16 
ABA). Five patients (15%) needed a 
therapeutic switch (one patient from 
TCZ to ABA, and 4 patients from ABA 
to TCZ). Among the TCZ IV group, all 
patients experienced a response (57% 
complete response and 43% partial re-
sponse). Among the TCZ SC group, 7 ex-
perienced a clinical response (complete 
in 67% and partial in 16%). Among the 
ABA group, 10 patients (62%) achieved 
either complete (5 patients) or partial 
(5) response, respectively. 
After 12 months of therapy, 100% of 
patients in TCZ groups, both IV and 
SC, and 7 (43%) of ABA group were 
receiving doses of oral prednisone not 
exceeding 7.5 mg/day as maintenance. 
Conclusion. Both TCZ and ABA can 
be proposed as an effective therapeutic 
option in GCA with relevant inflamma-
tory symptoms. ABA can be considered 
in the patient with absolute or relative 
or contraindications to TCZ.
Introduction
Giant cell arteritis (GCA) belongs to a 
group of immune-mediated diseases af-
fecting vessels of large size. It is con-
sidered a rare disease, but among the 
primary systemic vasculitis is the most 
prevalent (1, 2), and is characterised by 
high morbidity and mortality. In 1932, 
Horton et al. described the picture of a 
patient suffering from blindness, necro-
sis of the tongue, and mandibular clau-
dication that they referred to a new clin-
ical entity (3), the characteristic vessel 
wall infiltration by T lymphocytes and 
macrophages, with giant cells. It is his-
tologically characterised by intimal hy-
perplasia, granulomatous lesions, and 
the disruption of of the elastic fibres (4). 
GCA mainly affects people over 50 
years. The prevalence is greater in 
Scandinavia and North American than 
in South Europe, and black people are 
only occasionally affected. Geographi-
cal differences and occasional fam-
ily clustering suggest a role for either 
environmental or infectious or genetic 
factors (2). A genetic predisposition in 
subjects with the HLA-DRB1*04 allele 
is recognised (5).
The histologic changes of GCA are 
especially relevant in temporal artery, 
a traditional milestone of diagnosis. 
However, there is a marked heterogene-
ity in histopathology findings in biopsy 
samples from different patients. Only 
half of the positive biopsies show mult-
inucleated giant cells associated with 
granulomatous infiltrates, including 
CD41 T-cells and macrophages detected 
at the intima-media junction. In the oth-
er cases, the histopatology findings are 
characterised by lympho-mononuclear-
infiltrates with panarteritis features, oc-
casionally including granulocytes in the 
absencee of giant cells. A minority of 
the cases present with periadventitial 
vessels and/or vasa vasorum inflamma-
tion (6). Of special clinical importance, 
arterial wall thickening with partial or 
complete occlusion of the lumen (with 
ischaemic sequaele) can lead to anterior 
ischaemic optic neuropathy (7).
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Therapy has rapidly progressed in these 
years, achieving prolonged survival 
and, occasionally, definitive healings. 
Therapy of CGA has been centered 
on the use of glucocorticoids (GCs) 
(8) with immunosuppressive agents, 
e.g. methotrexate (MTX), considered 
as GCs-sparing therapy or in cases of 
refractory/resistant cases. Neverthe-
less, results in terms of efficacy have 
not been well established (8). While 
numerous biologic agents have been 
proposed over the last decades to con-
trol GCA, the recombinant humanised 
anti-IL-6 receptor antibody, tocilizum-
ab (TCZ), is the sole avaialbe biologic 
agent currently approved for this indi-
cation. It proved to be effective in im-
proving clinical manifestations, having 
a GCs-sparing effect and reducing the 
rate of relapses both in clinical trials 
and in real-life studies (9-11). 
Some data suggest a possible role for 
abatacept (ABA), a fusion protein 
composed of the Fc region of the im-
munoglobulin IgG1 and the extracel-
lular domain of CTLA-4. Some data 
showed that inappropriate activation, 
development, and overexpression of 
antigen-presenting adventitial dendrit-
ic cells (11) are involved in the early 
stages of the pathogenis of GCA. These 
cells create an ideal environment for 
microbial pathogens via the action of 
toll-like receptors (TLRs). Due to their 
vessel-specifcity, TLR profiles might 
justify the typical vessel involment 
charaterising GCA (12).
In order to activate T cell, the antigen-
presenting cell must present two sig-
nals: the MHC complexed with the 
antigen, and the co-signaling of CD80 
or CD86 molecule. Binding the CD80 
and CD86 molecule, ABA inihibits the 
second signal. In randomised controlled 
trials (RCT), ABA proved to be signifi-
cantly more effective compared to pla-
cebo for the management of GCA. In 
the intent-to-treat analysis of the 41 pa-
tients randomised to receive ABA (20 
patients) or placebo (20 patients) the 
relapse-free survival at 12 months was 
higher for ABA than placebo, and the 
median duration of remission signifi-
cantly prolonged (13).
The present study aimed at evaluating 
the efficacy of ABA compared to TCZ, 
assumed as a gold standard biologic 
treatment.
Methods
Data from 33 GCA consecutive patients 
recruited at the San Giovanni Bosco 
Hub Hospital in Turin (north-west 
Italy) between 2016 and 2018 were 
prospectively collected. Diagnosis 
was based on clinical and histological 
ground, each patient having a temporal 
artery biopsy-proven diagnosis (Figs. 
Fig. 1. Simplifying histological findings in temporal artery biopsy from one patient involved in the 
study. A: vessel lumen; B: lymphocyte and monocyte infiltrates; C: granulomatous lesion; D: intimal 
hyperplasia.
Fig. 2. Magnification of the granulomatous lesion. A: giant cell; B: eosinophils; C: lymphocyte and 
monocyte infiltration.
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1 and 2). Odd patients (from 1 to 33) 
were assigned to TCZ, given either 
intravenously (IV) (8 mg/kg/month), 
#8 cases, or subcutaneously (SC) (162 
mg/week), #9, based on the patient’s 
preference. ABA was administered 
SC at the dose of 125 mg/week in 16 
even patients (from 2 to 32). Biological 
therapies were prescribed in addition to 
oral prednisone 50 mg/day for 2 weeks 
(tapered to 20 mg/day by the end of the 
3rd month and then slowly tapered un-
til discontinuation within 6 months). In 
patients who were receiving mycophe-
nolate mofetil (MMF) or MTX (Table 
I), biological agents were started after 
conventional synthetic disease-modify-
ing antirheumatic drugs (csDMARDs) 
discontinuation.
Table I summarises the patients’ main 
characteristics.
Complete response to treatment after 12 
months of therapy was defined, based 
on clinical (disappearance of symp-
toms), imaging (ultrasound reversal of 
abnormalities) and serological [nor-
malisation of erythrocyte sedimenta-
tion rate (ESR) and C reactive protein 
(CRP)] ground. Partial response was 
defined as a substantial amelioration of 
clinical manifestations and serological 
parameters with persistent ultrasound 
abnormalities at one-year.
Efficacy and safety outcomes were as-
sessed every three months or in case of 
clinical changes.
Eleven out of 16 cases treated wit ABA 
could be examined for the presence of 
CD80 staining. 
Statistical analysis
For the comparison of variables at 
baseline and follow-up, Student’s t-
test was used for normally distributed 
parameters and the non-parametric 
Mann-Whitney test for non-normally 
distributed parameters. For these anal-
yses, the SPSS (IBM Corporation, NY, 
USA) software was used. p<0.05 was 
considered statistically significant.
Results
This prospective study included 33 
GCA patients [mean age 74 (range 85-
57), females 63%, mean follow-up from 
GCA diagnosis 44.4±33.5 months)].
A single biologic agent was admin-
istered in 28 patients out of 33 (85%) 
(8 TCZ IV, 9 TCZ SC, and 16 ABA). 
Five patients (15%) needed a thera-
peutic switch (one patient from TCZ to 
ABA for referred general malaise the 
day after the drug administration, and 
4 patients from ABA to TCZ for lack 
of efficacy).
No difference was observed in terms of 
baseline disease symptoms, vessel in-
volvement, sex, age, comorbidities when 
comparing the TCZ and ABA groups. 
In 17 patients, biological treatment (8 
TCZ and 9 with ABA) was started be-
cause of a disease relapse despite on-
going therapy.
Among the TCZ IV group, all patients 
experienced a response (57% complete 
response and 43% partial response). 
Among the TCZ SC group, 7 experi-
enced a clinical response (complete in 
67% and partial in 16%). Among the 
ABA group, 10 patients (62%) achieved 
either complete (5 patients) or partial (5 
patients) response, respectively. 
After 12 months of therapy, 100% of 
patients in TCZ groups, both IV and 
SC, and 7 (43%) of ABA group were 
receiving doses of oral prednisone not 
exceeding 7.5 mg/day as maintenance 
(Table II). A significant reduction in in-
flammatory parameters (CRP and ESR) 
Table I. Characteristics of GCA patients included in the study.
 Total number of patients (33) %
Demographic characteristics  
Female/male 21/12 
Age (years) (mean, SD) 73.6 ± 8.7 
Clinical characteristics at the onset of GCA  
Fever (n) 12 36.4
Fatigue (n) 18 54.5
Headache (n) 28 84.8
Scalp tenderness (n) 8 24.2
Jaw claudication (n) 15 45.4
Vision loss (n) 16 48.5
Polymyalgia rheumatica (n) 11 33.3
Diagnosis  
Biopsy-proven 27/32 84.4
Positron emission tomography positivity 12/29 41.4
Eco-colour-Doppler positivity 30/31 97.0
GC therapy  
Previous methylprednisolone pulses (n) 7 21.2
Oral prednisone (n) 33 100.0
Dose of oral prednisone (mg/day) (mean, SD) 49.7 ± 15.1 
Previous immunosuppressive therapies  
Methotrexate (n) 11 33.3
          mean dose (mg/week) (mean, SD) 15.6 ± 1.7 
Mycophenolate (n) 11 33.3
          mean dose (mg/day) (mean, SD) 2.2 ± 0.4 
Table II. Dose of GCs at baseline, 6 months, and 12 months as well as the number of 
switches due to lack of efficacy.
 TCZ=17 ABA=16 p
Mean GCs dose at baseline 50 mg/day 50 mg/day NS
  
Mean GCs dose at 6 months 0 mg/day 2.5 mg/day NS
  (min 0-max 10)
N° of patients on PDN >7.5 mg/day 0 4 0.0445
  
Mean GCs dose at 12 months 0.8 mg/day 5.6 mg/day NS
  (min 0-max 10)
N° of patients on PDN >7.5 mg/day 0 9 0.0003
  
N° of switch for lack of efficacy 0 4 0.0445
TCZ: tocilizumab; ABA: abatacept; GCs: glucocorticoids; PDN: prednisone.
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was observed after 12 months of ther-
apy with TCZ: TCZ IV group: mean 
baseline CRP (mg/dl) 3.9±2.3, mean 
CRP after 12 months of therapy 0.3±0.2 
(p<0.01); mean baseline ESR (mm/h) 
58.1± 25.6, mean ESR after 12 months 
9.5±4.2 (p<0.01); TCZ SC group: mean 
baseline CRP 4.5±3.8, mean CRP af-
ter 12 months 0.2±0.2 (p<0.01); mean 
baseline ESR 51.9±27, mean ESR after 
12 months 6.5±6, p<0.01].
With regard to ABA, mean baseline 
ESR and CRP were 57.8±35.8 and 
3.8±3.1, respectively, and 8.7±7.1 and 
0.3±0.2 at 12 months (p<0.01 for both 
parameters).
Of the 11 cases treated with ABA that 
could be examined for CD80 staining, 
10 were positive. Three of them showed 
complete remission, 5 had partial remis-
sion and 2 were non-responders. The 
negative case had a complete response. 
One out of the 5 remaining cases who 
could not be analysed for CD80 stain-
ing had a complete remission.
When compared to standard GCs regi-
men (8), in patients treated with TCZ, 
we estimated a median steroid-sparing 
effect of 30 mg daily in the first month 
and an overall steroid-sparing effect 
of 15 mg daily when assessed in 12 
months.
No significant difference in outcomes 
was observed when comparing relaps-
ing patients with newly diagnosed 
CGA. No significant side effect related 
to biological administration was re-
corded.
Discussion
GCA is considered the most prevalent 
vasculitis in elderly people, especially 
in western countries. It is characterised 
by severe mortality and morbility, in-
cluding permanent visual loss.
The therapy for GCA has been cen-
tered on GCs. While the use of GCs 
has been associated to an excellent rate 
of response, yet relapses are frequent 
when GCs are tapered and their pro-
longed use is associated to metabolic 
and infective complications (14), pav-
ing the way for the search of alternative 
options for the management of GCA. 
Among the conventional immunosup-
pressant agents, MTX has been the 
most commonly reported, especially 
in cases of refractory GCA, albeit with 
only modest results.
The positive results of RCTs showing 
the efficacy of TCZ in both newly di-
agnosed and in relapsing cases of GCA 
(9-11) led to the approval of its use for 
the management of GCA. Results for 
RCTs were mirrored by those coming 
from real-life experience, further sup-
porting the inclusion of TCZ in the 
therapeutic harmamentarium for the 
management of GCA, especially in re-
fractory cases. ABA was proven to be 
more effective than placebo in treating 
GCA patients (13).
This is the first study that has compared 
the effectiveness of these two biologic 
agents in treating GCA.
In our experience, both TCZ and ABA 
(though at a lesser extent) showed sig-
nificant sparing effects on steroid dose, 
and proved to limit the risk of disease 
re-exacerbation. Compared to ABA, 
TCZ showed to be more effective both 
in inducing a clinical response and 
sparing steroids.
CD80 staining revealed to be almost in-
variably positive in biopsies of tempo-
ral artery. A positive staining cannot be 
used as a predictor of clinical response 
to ABA. A negative staining does not 
affect response to ABA. 
However, we acknowledge that our 
study is limited by the lack of randomi-
sation and the relatively small sample 
size. Larger randomised trials are need-
ed to address this topic in a definite way. 
Similarly, some degree of heterogeneity 
in previous treatment exists when refer-
ring to the use of steroids. 
Both TCZ and ABA can be proposed as 
an effective therapeutic option in cases 
of GCA with relevant inflammatory 
symptoms. 
Although significant, in this study the 
effect of ABA seemed to be moderate 
and arose concerns about its position 
as a first- or second-line therapeutic ap-
proach.
While further studies are still needed 
for including ABA in the standard 
treatment of severe cases of GCA, a 
putative role can be envisaged in the 
patients with absolute or relative or 
contraindications to TCZ, such as those 
with diverticulitis, hepatopathies, and 
hypercolesterolaemia.
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